Stay updated with the latest glucagon-like-peptide-1 news, articles, and insights from trusted sources. Explore in-depth coverage and expert analysis on glucagon-like-peptide-1 topics.
Bengaluru: Biocon Limited has achieved a regulatory milestone in the United States, reinforcing its presence in the global diabetes treatment market. Biocon Pharma Limited, a subsidiary of Biocon Limited, has received approval from the U.S. Food and Drug Administration for Dapagliflozin Tablets in 5 mg and 10 mg strengths. The approval enables the company to market the drug for adults with type 2 diabetes mellitus, expanding its footprint in one of the world's largest pharmaceutical markets. T ...Read More >
New Delhi, Apr 7 (PTI) As prices tumble and generic versions of GLP-1-based weight-loss drugs flood the market, a quiet frenzy is unfolding that has doctors and authorities alarmed. Medicines that are strictly prescription-based are being bought over the counter with their use expanding beyond clinical settings, often with little medical advice. For many people eager to lose weight quickly, the promise of fast results is overshadowing concerns about safety. Important factors -- like correct do ...Read More >
Indian brides are turning to low-cost weight-loss injections ahead of their weddings. Freepik ShowQuick Read Summary is AI-generated, newsroom-reviewed * Soon-to-be Indian brides and grooms increasingly seek weight-loss drugs before weddings * Mounjaro is preferred over Wegovy and prescribed only for medically eligible patients * Regulators warn against misuse amid cheaper local weight-loss drug versions flooding market Did our AI summary help? Let us know. Switch To Beeps Mode Soon-to ...Read More >
HYDERABAD, India, April 3 (Reuters) - Soon-to-be brides and grooms seeking shortcuts to shed pounds before the big day have become the latest consumer target for weight-loss drugs in India. New Delhi wellness clinic Klarity Skin Clinic touts a "Mounjaro bride" package, while other clinics have woven weight-loss injections into "pre-wedding" transformation packages typically focused on skin treatments and hairstyle makeovers. In a social media video, Klarity offers "guided nutrition, Mounjar ...Read More >
HYDERABAD, India, April 3 (Reuters) - Soon-to-be brides and grooms seeking shortcuts to shed pounds before the big day have become the latest consumer target for weight-loss drugs in India. New Delhi wellness clinic Klarity Skin Clinic touts a "Mounjaro bride" package, while other clinics have woven weight-loss injections into "pre-wedding" transformation packages typically focused on skin treatments and hairstyle makeovers. In a social media video, Klarity offers "guided nutrition, Mounjaro ...Read More >
HYDERABAD: Soon-to-be brides and grooms seeking shortcuts to shed pounds before the big day have become the latest consumer target for weight-loss drugs in India. New Delhi wellness clinic Klarity Skin Clinic touts a "Mounjaro bride" package, while other clinics have woven weight-loss injections into "pre-wedding" transformation packages typically focused on skin treatments and hairstyle makeovers. In a social media video, Klarity offers "guided nutrition, Mounjaro and smart workouts" to prepa ...Read More >
HYDERABAD: Soon-to-be brides and grooms seeking shortcuts to shed pounds before the big day have become the latest consumer target for weight-loss drugs in India. New Delhi wellness clinic Klarity Skin Clinic touts a "Mounjaro bride" package, while other clinics have woven weight-loss injections into "pre-wedding" transformation packages typically focused on skin treatments and hairstyle makeovers. Also Read: Weight-loss drug boom: Will cheaper Ozempic generics shake up India's fitness and nut ...Read More >
NEW DELHI: With prices of GLP-1 drugs crashing and their generic versions flooding the market, govt has cracked down on their misuse, inspecting 49 businesses and issuing notices while also flagging risks of unsupervised consumption in a detailed advisory.To ensure ethical pharmaceutical practices, Drug Controller General of India has intensified surveillance of unauthorised sale and promotion of the drugs. In India, GLP-1 medicines can be prescribed only by endocrinologists, internal medicine s ...Read More >
NEW DELHI, Apr 1: The GLP-1 based weight loss drugs are prescription medications used to treat type 2 diabetes and obesity but carry serious side effects and must only be taken under the supervision of a qualified medical specialist, the government said on Wednesday. Highlighting that multiple variants of GLP-1 drugs have been recently introduced in the Indian market, and concerns have emerged regarding their on-demand availability through retail pharmacies, online platforms, wholesalers, and we ...Read More >
New Delhi [India], April 1 (ANI): The Government of India on Thursday released details on the GLP -1 Drugs' use, risks, and regulation, according to an official press release. Diabetes is a chronic disease that occurs when the pancreas does not produce adequate insulin, or when the body cannot effectively use the insulin it produces, leading to high blood sugar. If left untreated, it can lead to complications like blindness, kidney failure, heart attacks, stroke and lower limb amputation. Also ...Read More >
New Delhi [India], April 1 (ANI): The Government of India on Thursday released details on the GLP -1 Drugs' use, risks, and regulation, according to an official press release. Diabetes is a chronic disease that occurs when the pancreas does not produce adequate insulin, or when the body cannot effectively use the insulin it produces, leading to high blood sugar. If left untreated, it can lead to complications like blindness, kidney failure, heart attacks, stroke and lower limb amputation. Insu ...Read More >
A ₹1,000 crore market is set to grow 5x to ₹5,000 crore by 2030 as prices drop 40-50% post patent expiry. Three early movers are taking sharply different routes -- low-cost, premium, and partnerships in a high-stakes land grab. The Indian market for Glucagon-Like Peptide-1 (GLP-1) therapies is currently at an inflection point and is poised for strong expansion. The current market size for anti-obesity and diabetes GLP-1 drugs in India, as of 2025, is estimated to be between ₹1,000-1,200 cr ...Read More >
New Delhi, Dec 15 (PTI) Biocon Ltd on Monday said it has launched its diabetes and chronic weight management injection, Liraglutide, in the Netherlands through its distribution partner, Pharmamedic BV. The drug-device combination will be marketed in the Netherlands under the brand names Diavorin for diabetes and Vobexoryn for chronic weight management, Biocon said in a statement. Liraglutide is a synthetic analog of GLP-1 peptide (glucagon-like peptide-1) that helps lower blood sugar levels an ...Read More >
Bengaluru: Bangalore are you tired of trying viral trends and 'magic remedies' from social media to reduce weight? Today's youth want to be healthy, but a lack of correct information often leads them down the wrong path. Obesity is a complex medical condition that cannot be solved by a two-day diet or a viral challenge. What one needs is a scientific and reliable approach. The good news is that modern science now has a solution - called GLP1 RA (glucagon-like-peptide receptor agonist). This is a ...Read More >
India has officially approved the use of Ozempic (semaglutide), a once-a-week injection designed for adults with type 2 diabetes. Approved by the Central Drugs Standard Control Organisation (CDSCO), this drug has made headlines worldwide not just for diabetes management but also for its weight loss effects. As India faces rising rates of diabetes, Ozempic's arrival is more than just a medical update, it could influence lifestyle choices for millions.Here's all we need to know about what this new ...Read More >
New Delhi [India], September 30 (ANI): The Central Drugs Standard Control Organisation (CDSCO) has approved Danish drugmaker Novo Nordisk's once-a-week injection for patients suffering from Type 2 diabetes. Also Read | Durga Puja 2025: PM Narendra Modi Participates in Durga Puja Celebrations in Delhi's CR Park on Occasion of Maha Ashtami, Prays for Everyone's Happiness and Wellbeing (See Pics). In a statement provided to ANI, Novo Nordisk has stated that Ozempic is intended for individuals wit ...Read More >
MUMBAI, Sept 25 (Reuters) - Eli Lilly (LLY.N), opens new tab plans to bring its experimental oral weight-loss drug orforglipron to India as it sees market potential in the world's most populous nation, a senior executive said on Thursday. "I do think there is promise for products like that (orforpligron) in India, if it does get approved," Winselow Tucker, Lilly India's president said at an event in Mumbai. Tucker, however, did not indicate when Lilly plans to launch the drug. The drugmaker h ...Read More >
New Delhi [India], August 25 (ANI): India's contract research, development, and manufacturing organisation (CRDMO) sector is emerging as one of the most dynamic growth stories in the global pharmaceutical landscape. According to a recent Jefferies India report, the country's CRDMO, which has already reached revenues of around USD 3 billion, has grown at a compound annual growth rate (CAGR) of 14 per cent over the past five years. The report highlights that India's CRDMO industry has caught the ...Read More >
SCHOTT, a leader in specialty glass, initiates local production of high-precision glass tubing for syringes and cartridges in Gujarat, India. This marks a significant step in India's pharmaceutical sector, aligning with the 'Make in India' initiative, enhancing SCHOTT's role in the Asian market. In a notable development in India's pharmaceutical landscape, SCHOTT has successfully commenced local production of high-precision glass tubing for syringes and cartridges at its Jambusar, Gujarat facil ...Read More >
READ MORE: Ozempic-maker's new fat-busting drug cuts body weight by a quarter - and it comes as a jab or a PILL The Ozempic boom has seen a drug widely used to treat diabetes and manage obesity in adults transform into 'miracle' weight loss jab that's coveted by anyone with a few extra kilos to shed. Ozempic and other alternatives like Mounjaro and Wegovy are all different brand names for the drug semaglutide that mimics the the actions of GLP-1 - a hormone in the brain that regulates appetite ...Read More >
New Delhi, Nov 26: The popular glucagon-like peptide-1 (GLP-1) receptor agonists known to help in weight loss as well as manage blood sugar can also protect the kidneys, regardless of diabetes status, finds a study led by an Indian-origin researcher. Originally developed to treat diabetes, GLP-1 receptor agonists have significant benefits in people with and without diabetes, according to the study published in The Lancet Diabetes & Endocrinology. The drug stimulates insulin production and low ...Read More >
Stay updated with the latest None news, articles, and insights from trusted sources. Explore in-depth coverage and expert analysis on None topics.